During each phase of a clinical trial, we evaluate the safety and efficacy of a drug candidate to determine its evolving benefit–risk profile. If the risk exceeds the patient benefit and the risk cannot be managed by acceptable measures, then we change the trial conduct or stop development of the medicine.
We also publish the results, positive as well as negative, of our clinical trials in various medical and professional journals to inform healthcare professionals, researchers, patients and the public about potential new therapies under development.